Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2562)	4/28/1999 7:15:00 PM
From: Art Vandelay AIA	Read Replies (1) \| Respond to of 10280

I don't believe that it is an extension deal. Waxman Hatch just precluded ANDA applications which is what a generic app is. So to summarize. SEPR can file on Zyrtec in 2002 while the generics are out until 2007. However, I don't believe this is true regarding Meridia. I think both SEPR and the generic can launch in 2002. That may be why SEPR intends to develop this themselves.

To: Biomaven who wrote (2562)	4/28/1999 7:17:00 PM
From: David Howe	Respond to of 10280

FYI Today, Datek and potentially other brokers raised their margin requirements (to 50%) for SEPR due to volatility. This is possibly why we saw increased selling pressure today. Some people will be forced to sell at these levels in order to meet the margin call. The large drop today was on very low volume. The margin requirements for the internet stocks was raised 6 months ago or so. It caused a minor dip but they have since exploded to the upside. Another reason for the recent weakness is the continued shift from the high flyers into cyclicals. This has affected the whole drug and biotech sector as well as the tech stocks. IMO the shift is nearly complete and we will see an up trend in SEPR reestablished in the near future. Dave